Long QT syndrome caused by noncardiac drugs

Progress in Cardiovascular Diseases

Volumn 45, Issue 5, 2003, Pages 415-427

  Viskin, Sami ^a   Justo, Dan ^a   Halkin, Amir ^a   Zeltser, David ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOKALANT; AMANTADINE; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BEPRIDIL; CHLOROQUINE; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DISOPYRAMIDE; DOFETILIDE; ERYTHROMYCIN; FLUCONAZOLE; GATIFLOXACIN; GREPAFLOXACIN; IMIDAZOLE DERIVATIVE; KETOCONAZOLE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; NEUROLEPTIC AGENT; PENTAMIDINE; PROCAINAMIDE; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOTALOL; SPARFLOXACIN; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANAMNESIS; BRADYCARDIA; DNA POLYMORPHISM; DRUG INDUCED DISEASE; ELECTROCARDIOGRAPHY; GENDER; HEART ARRHYTHMIA; HEART DISEASE; HIGH RISK PATIENT; HUMAN; HYPOKALEMIA; INCIDENCE; LONG QT SYNDROME; MITRAL VALVE PROLAPSE; QT INTERVAL; REVIEW; RISK FACTOR; TORSADE DES POINTES;

EID: 0037356240     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2003.00101     Document Type: Review

References (42)

1. Viskin S: The long QT syndromes and torsade de pointes. Lancet 354:1625-1633, 1999
2. Chiang CE, Roden DM: The long QT syndromes: Genetic basis and clinical implications. J Am Coll Cardiol 36:1-12, 2000
3. De Ponti F, Poluzzi E, Montanaro N: QT-interval prolongation by non-cardiac drugs: Lessons to be learned from recent experience. Eur J Clin Pharmacol 56:1-18, 2000
4. Jervell A, Lange-Nielsen F: Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 54:59-68, 1957
5. Romano C, Gemme G, Pongiglione R: Aritmie cardiache rare dell'eta pediatrica. Clin Pediatr 45:656-683, 1963
6. Ward OC: A new familial cardiac syndrome in children. J Irish Med Assoc 54:103-106, 1964
7. Selzer A, Wray HW: Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30:17-26, 1964
8. Jackman WM, Friday KJ, Anderson JL, et al: The long QT syndromes: A critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 31:115-172, 1988
9. Schoonmaker F, Osten R, Greenfield J: Thioridazine (mellaril) induced ventricular tachycardia controlled with an artificial pacemaker. Ann Intern Med 65:1076-1078, 1966
10. Kr potassium channel. Cell 81:229-307, 1995
11. Vincent GM, Timothy KW, Leppert M, et al: The spectrum of symptoms and QT intervals in carriers of the gene for the long QT syndrome. N Engl J Med 327:846-852, 1992
12. Allan WC, Timothy KW, Vincent GM, et al: Long QT syndrome in children: The value of rate corrected QT interval and DNA analysis as screening tests in the general population. J Med Screen 8:173-177, 2001
13. Roden DM, Lazzara R, Rosen M, et al: Multiple mechanisms in the long QT syndrome. Current knowledge, gaps, and future directions. Circulation 94:1996-2012, 1996
14. Antzelevitch C, Sicouri S: Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol 23:259-277, 1994
15. El-Sherif N, Chinushi M, Caref EB, et al: Electrophysiological mechanism of the characteristic electrocardiographic morphology of torsade de pointes tachyarrhythmias in the long QT syndrome. Detailed analysis of ventricular tridimensional activation patterns. Circulation 96:4392-4399, 1997
16. Vitola J, Vukanovic J, Roden DM: Cisapride-induced torsade de pointes. J Cardiovasc Electrophysiol 9:1109-1113, 1999
17. Haverkamp W, Breithardt G, Camm AJ, et al: The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report of a Policy Conference of the European Society of Cardiology. Eur Heart J 21:1216-1231, 2000
18. Zabel M, Hohnloser SH, Behrens S, et al: Electrophysiologic features of torsade de pointes: Insights from a new rabbit heart model. J Cardiovasc Electrophysiol 8:1148-1158, 1997
19. Carlsson L, Almgren O, Duker G: QTU-prolongation and torsade de pointes induced by putative class III antiarrhythmic agents in the rabbit: Etiology and interventions. J Cardiovasc Pharmacol 16:276-285, 1990
20. Malik M: Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 12:411-420, 2001
21. Sesti F, Abbott GW, Wei J, et al: A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 97:10613-10618, 2000
22. Wei J, Yang ICH, Tapper AR, et al: KCNE1 polymorphism confers risk of drug-induced long QT syndrome by altering kinetic properties of IKs potassium channels. Circulation 100:1-495, 1999 (abstr)
23. Yang P, Wei J, Murray KT, et al: Frequency of ion channel mutations and polymorphisms in a large population of patients with drug-associated long QT syndrome. PACE 24:579, 2001 (abstr)
24. Yang R, Kanki H, Drolet B, et al: Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105:1943-1948, 2002
25. Roden DM: Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res 50:224-231, 2001
26. Viskin S, Zeltser D, Justo D, et al: Torsade de pointes due to medications administered for non-cardiac indications: Most patients have risk factors that can be easily identified. PACE 24:635, 2002 (abstr)
27. Statters DJ, Malik M, Ward DE, et al: QT dispersion: Problems of methodology and clinical significance. J Cardiovasc Electrophysiol 5:672-685, 1994
28. Boyle NG, Weiss JN: Making QT correction simple is complicated. J Cardiovasc Electrophysiol 12:421-423, 2001
29. Napolitano C, Schwartz PJ, Brown AM, et al: Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life threatening arrhythmias. J Cardiovasc Electrophysiol 11:691-696, 2000
30. Makkar RR, Fromm BS, Steinman RT, et al: Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs. JAMA 270:2590-2597, 1993
31. Yang T, Roden DM: Extracellular potassium modulation of drug block of IKr: Implications for torsades de pointes and reverse use-dependence. Circulation 93:407-411, 1996
32. Wysowski DK, Baksanyi J: Cisapride and fatal arrhythmias [letter]. N Engl J Med 335:290-291, 1996
33. Hill SL, Evangelista JK, Pizzi AM, et al: Proarrhythmia associated with cisapride in children. Pediatrics 101:1053-1056, 1998
34. Honig PK, Wortham DC, Zamani K, et al: Terfenadineketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269:1513-1518, 1993
35. Roden DM: Taking the "idio" out of "idiosyncratic:" Predicting torsades de pointes. PACE 21:1029-1034, 1998
36. Maruyama T, Ohe T, Kutia T, et al: Physiological and pathological responses of TU waves to class 1a antiarrhythmic drugs. Eur Heart J 16:667-673, 1995
37. Viskin S, Barron HV, Olgin J, et al: The treatment of atrial fibrillation: Pharmacologic and non-pharmacologic strategies. Curr Prob Cardiol 22:37-108, 1997
38. Viskin S, Fish R, Roden DM: Drug induced torsade de pointes, in Braunwald E, Fauci SA, Isselbacher KJ, et al, eds. Harrison's Principles of Internal Medicine (14th ed). Harrison's on-line, available: http//harrisonsonline.com; 2000, p 231
39. Gbadebo TD, Trimble RW, Khoo MSC, et al: Calmodulin inhibitor W-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes. Circulation 105:770-774, 2002
40. Viskin S: Torsades de pointes. Curr Treatment Options Cardiovasc Med 1:187-195, 1999
41. Antzelevitch C, Nesterenko DD: Contribution of electrical heterogeneity of repolarization to the electrocardiogram, in Gussak I, Antzelevitch C, eds. Cardiac Repolarization. Bridging Basic and Clinical Science. New York: Humana Press, 2002
42. Malik M, Farbom P, Batchvarov K, et al: Relation between QT and RR intervals is highly individual among healthy subjects: Implications for heart rate correction of the QT interval. Heart 87:220-228, 2002